Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

1.6K
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.6K
Seizures: Classification01:13

Seizures: Classification

1.9K
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
1.9K
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

1.5K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.5K
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

880
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
880
Antiepileptic Drugs: Calcium Channel Blockers01:17

Antiepileptic Drugs: Calcium Channel Blockers

1.5K
Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
1.5K
Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders01:27

Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders

2.3K
Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
2.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

New onset refractory status epilepticus (NORSE) versus refractory status epilepticus not meeting NORSE criteria: A comparative clinical and electroencephalography-based study.

Epilepsia·2026
Same author

Activity-dependent antioxidant gene therapy protects against epileptogenesis.

Signal transduction and targeted therapy·2026
Same author

Energy metabolism, adenosine, and glutamate signaling reprogramming by decanoic acid in Glut1 disorder syndrome.

Epilepsia open·2026
Same author

The heartbeat evoked potential and the prediction of functional seizure semiology.

Brain communications·2026
Same author

Metabolic targeting of pantothenate by medium chain fats in glioblastoma cells.

BMC cancer·2026
Same author

Dual mechanism of anti-seizure medications in controlling seizure activity.

Brain communications·2026

Related Experiment Video

Updated: Mar 9, 2026

Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus
08:28

Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus

Published on: April 5, 2011

18.2K

Pathophysiology of status epilepticus.

Matthew C Walker1

  • 1Department of Clinical and Experimental Epilepsy, UCL Institute of Neurology, London WC1N 3BG, United Kingdom.

Neuroscience Letters
|December 25, 2016
PubMed
Summary

Status epilepticus (SE), a severe epilepsy form, involves failed seizure termination mechanisms. Prolonged seizures become drug-resistant, leading to neuronal death and potential long-term neurological issues.

Keywords:
Drug resistanceExcitotoxicityMitochondriaReactive oxygen speciesStatus epilepticus

More Related Videos

Long-term Continuous EEG Monitoring in Small Rodent Models of Human Disease Using the Epoch Wireless Transmitter System
08:43

Long-term Continuous EEG Monitoring in Small Rodent Models of Human Disease Using the Epoch Wireless Transmitter System

Published on: July 21, 2015

26.4K
Preparation and Implantation of Electrodes for Electrically Kindling VGAT-Cre Mice to Generate a Model for Temporal Lobe Epilepsy
09:29

Preparation and Implantation of Electrodes for Electrically Kindling VGAT-Cre Mice to Generate a Model for Temporal Lobe Epilepsy

Published on: August 17, 2021

2.9K

Related Experiment Videos

Last Updated: Mar 9, 2026

Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus
08:28

Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus

Published on: April 5, 2011

18.2K
Long-term Continuous EEG Monitoring in Small Rodent Models of Human Disease Using the Epoch Wireless Transmitter System
08:43

Long-term Continuous EEG Monitoring in Small Rodent Models of Human Disease Using the Epoch Wireless Transmitter System

Published on: July 21, 2015

26.4K
Preparation and Implantation of Electrodes for Electrically Kindling VGAT-Cre Mice to Generate a Model for Temporal Lobe Epilepsy
09:29

Preparation and Implantation of Electrodes for Electrically Kindling VGAT-Cre Mice to Generate a Model for Temporal Lobe Epilepsy

Published on: August 17, 2021

2.9K

Area of Science:

  • Neuroscience
  • Epilepsy Research
  • Cellular Biology

Background:

  • Status epilepticus (SE) represents a critical neurological emergency with significant morbidity and mortality.
  • SE arises from the failure of natural seizure-terminating mechanisms, with seizure duration inversely correlating with the likelihood of spontaneous cessation.
  • Recent findings highlight a transition from desynchronized to synchronized neuronal states during SE, impacting seizure termination.

Purpose of the Study:

  • To elucidate the cellular and molecular mechanisms underlying the progression and refractoriness of status epilepticus.
  • To understand the pathways leading to neuronal death and long-term consequences in SE.
  • To identify potential therapeutic targets for managing SE and its sequelae.

Main Methods:

  • Review of human and animal data on seizure dynamics and termination.
  • Analysis of molecular pathways involved in neuronal excitability and death during prolonged seizures.
  • Examination of receptor dynamics (e.g., GABA(A), NMDA) and intracellular signaling cascades.

Main Results:

  • SE becomes increasingly resistant to pharmacological treatments, such as benzodiazepines, partly due to GABA(A) receptor internalization.
  • Excessive NMDA receptor activation leads to calcium influx, activating pathways like nitric oxide synthase, calpains, and NADPH oxidase.
  • Mitochondrial dysfunction, including ATP depletion and permeability transition pore opening, contributes to neuronal death in SE.

Conclusions:

  • SE triggers complex downstream effects, including inflammation and blood-brain barrier disruption.
  • These pathological processes can precipitate long-term neurological deficits, such as chronic epilepsy and cognitive impairment.
  • Understanding SE's pathophysiology is crucial for developing effective interventions to prevent neuronal damage and improve patient outcomes.